Diabetes researchers are studying a drug known as difluoromethylornithine (DFMO) that may reduce stress in cells that make insulin and preserve the body’s own insulin production.
The Targeting Type 1 Diabetes via Polyamines (TADPOL) trial is currently seeking participants who were diagnosed with Type 1 diabetes within the past 100 days. Researchers are trying to learn whether DFMO may be a useful treatment to improve beta cell health for persons with Type 1 diabetes.
Video about the TADPOL trial
Phone: 816-460-1097
Email: endoclinicaltrials@cmh.edu
Phone: 414-955-8486
Email: T1Dinfo@mcw.edu
Phone: 317-278-8879
Email: tadpol@iu.edu
Phone: 773-702-9968
Phone: 734-615-4079
The purpose of this study is to determine if an investigational drug known as DFMO has an effect on reducing the amount of stress that is experienced by the body’s beta cells (the cells that make insulin) and preserves residual c-peptide (the body’s own insulin production). An investigational drug means it is not approved by the Food and Drug Administration (FDA).
By asking participants to take DFMO or a placebo (looks the same as the study drug but with no active ingredients), we hope to be able to learn more about whether DFMO may be a useful treatment to improve beta cell health for persons with Type 1 diabetes.
Participants in this study will receive:
The study's duration is approximately 12 months. There are six in-person visits and one phone visit.
The study is being conducted by Emily K. Sims, MD, and Linda A. DiMeglio, MD, MPH, at the Indiana University School of Medicine in the Division of Pediatric Endocrinology with support from the above-mentioned clinical research centers. It is funded by Breakthrough T1D. There is no cost for the study medication or study-related procedures, and participation is voluntary. If you would like to participate, please contact your nearest study location listed above or email tadpol@iu.edu.
